[1] Chun-Jen Liu.Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.J Gastroenterol Hepatol,2012,27:1555-1560.
[2] Gaggini M., Morelli M,Buzzigoli E,et al.Non-alcoholic fatty liver disease(NAFLD)and its connection with insulin resistance,dyslipidemia,atherosclerosis and coronary heart disease.Nutrients,2013,5:1544-1560.
[3] Gao X,Fan JG;Study Group of Liver and Metabolism,Chinese Society of Endocrinology.Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism,Chinese Society of Endocrinology. J Diabetes,2013,5: 406-415.
[4] Promrat K,Kleiner DE,Niemeier HM,et al. Randomized controlled trial testing the effects of weight loss onnonalcoholic steatohepatitis. Hepatology,2010,51:121-129.
[5] Charlton M,Krishnan A,Viker K,et al. Fast food diet mouse:novel small animal model of NASH with ballooning,progressive fibrosis,and high physiological fidelity to thehuman condition. Am J Physiol Gastrointest Liver Physiol,2011,301:825-834.
[6] Ross AB,Godin JP,Minehira K,et al.Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol,2013: 585876.
[7] Utzschneider KM,Bayer-Carter JL,Arbuckle MD,et al. Beneficial effect of a weight-stable,low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr,2013,109: 1096-1104.
[8] Ryan MC,Itsiopoulos C,Thodis T,et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol,2013,59:138-143.
[9] Abenavoli L,Milic N,Peta V,et al.Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.World J Gastroenterol,2014,20:16831-16840.
[10] Parker HM,Johnson NA,Burdon CA,et al. Omega-3 supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis.J Hepatol,2012,56: 944-951.
[11] Finelli C,Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease World J Gastroenterol,2012,18: 6790-6800.
[12] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology. Gastroenterology,2012,142: 1592-1609.
[13] Thoma C,Day CP,Trenell MI.Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol,2012,56: 255-266.
[14] Hallsworth K,Fattakhova G,Hollingsworth KG,et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss.Gut,2011,60: 1278-1283.
[15] Caiazzo R,Lassailly G,Leteurtre E,et al.Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-yearcontrolled longitudinal study.Ann Surg,2014,260: 893-898.
[16] Hassanian M,Al-Mulhim A,Al-Sabhan A,et al.The effect of bariatric surgeries on nonalcoholic fatty liver disease.Saudi J Gastroenterol,2014,20: 270-278.
[17] Bower G,Toma T,Harling L,et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg,2015,25: 2280-2289.
[18] Zelber-Sagi S,Kessler A,Brazowsky E,et al. A double-blind randomized placebo-controlled trial of orlistat for thetreatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2006,4: 639-644.
[19] Harrison SA,Fecht W,Brunt EM,et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: arandomized, prospective trial. Hepatology,2009,49: 80-86.
[20] Alswat KA.The role of endocannabinoids system in fatty liver disease and therapeutic potentials.Saudi J Gastroenterol,2013,19: 144-151.
[21] Mallat A,Teixeira-Clerc F,Lotersztajn S.Cannabinoidsignaling and liver therapeutics. J Hepatol,2013,59: 891-896.
[22] Musso G,Gambino R,Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. ObesRev,2010,11: 430-445.
[23] Lavine JE,Schwimmer JB,Van Natta ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA,2011,305: 1659-1668.
[24] Tsochatzis EA,Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther,2011,2: 1-5.
[25] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association. Hepatology,2012,55: 2005-2023.
[26] Van Wagner LB,Rinella ME.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol,2011,4: 249-263.
[27] Sanyal AJ,Chalasani N,Kowdley KV, et al. Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362: 1675-1685.
[28] Lutchman G,Modi A,Kleiner DE,et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology,2007,46: 424-429.
[29] Svegliati-Baroni G,Saccomanno S,Rychlicki C,et al. Glucagonlike peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int,2011,31: 1285-1297.
[30] Fan H,Pan Q,Xu Y,et al.Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol,2013,57: 702-708.
[31] Nseir W,Mograbi J,Ghali M.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.Dig Dis Sci,2012,57: 1773-1781.
[32] Merat S,Aduli M,Kazemi R,et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci,2008,53: 2246-2250.
[33] Xiang Z,Chen YP,Ma KF,et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol,2013,13:140.
[34] Ratziu V. Treatment of NASH with ursodeoxycholic acid:pro.Clin Res Hepatol Gastroenterol,2012,36: S41-S45.
[35] 李华茹.易善复治疗90 例非酒精性脂肪肝的临床疗效分析.中国现代药物应用,2013,7:78-79.
[36] Sumida Y,Naito Y,Tanaka S,et al.Long-term (& gt; =2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepatogastroenterology,2013,60: 1445-1450.
[37] Bjelakovic G,Nikolova D,Gluud LL,et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.JAMA,2007,297: 842-857.
[38] Schurks M,Glynn RJ,Rist PM,et al.Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials.BMJ,2010,341: c5702.
[39] Lippman SM,Klein EA,Goodman PJ,et al.Effect of selenium and vitamin E on risk of prostate cancer and othercancers: the Selenium and Vitamin E Cancer Prevention Trial(SELECT). JAMA,2009,301:39-51.
[40] Milosevi N,Milanovi M,Abenavoli L,et al.Phytotherapy and NAFLD-from goals and challenges to clinical practice.Rev Recent Clin Trials,2014,9: 195-203.
[41] Mukherjee S.Betaine and nonalcoholic steatohepatitis: back to the future? World J Gastroenterol,2011,17:3663-3664.
[42] Lo RS,Austin AS,Freeman JG.Is there a role for probiotics in liver disease ScientificWorldJournal,2014:874768.
[43] Ma YY,Li L,Yu CH,et al.Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.World J Gastroenterol,2013,19: 6911-6918.
[44] Kelishadi R,Farajian S,Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease;a systematic review on the current evidences. Hepat Mon,2013,13: e7233.
[45] Vajro P,Mandato C,Licenziati MR,et al.Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease.J Pediatr Gastroenterol Nutr,2011,52: 740-743.
[46] Malaguarnera M,Vacante M,Antic T,et al. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci,2012,57: 545-553.
[47] Qiang G,Zhang L,Yang X,et al.Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.Eur J Pharmacol,2012,685: 156-164.
[48] Valenti L,Dongiovanni P,Fargion S.Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol,2012,18:3782-3786.
[49] Beaton MD,Chakrabarti S,Levstik M,et al. Phase II clinical trial of phlebotomy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther,2013,37:720-729. |
